Table 4 Paediatric antiretroviral therapy (ART) utilization among children on second-line ART at data transfer in TREAT Asia and IeDEA Southern Africa
TREAT Asia (N = 137) | Â | IeDEA Southern Africa (N = 149) | ||
|---|---|---|---|---|
Female, N (%) | 69 (50) | Â | Female, N (%) | 49 (33) |
Most common regimens, N (%) | Â | Â | Most common regimens | Â |
AZT+3TC+LPV/r | 31 (23) | Â | AZT+ddI+LPV/r | 54 (36) |
AZT+ddI+LPV/r | 29 (21) | Â | AZT+ddI+EFV | 17 (11) |
ddI+3TC+LPV/r | 15 (11) | Â | AZT+TDF+LPV/r | 14 (9) |
LPV/r+IDV | 8 (6) | Â | ABC+3TC+LPV/r | 12 (8) |
d4T+ddI+LPV/r | 7 (5) | Â | d4T+3TC+LPV/r | 8 (5) |
Median age, months (IQR) at start | 120 (78-145) | Â | Median age, months (IQR) at start | 66 (29-112) |
Median age, months (IQR) at data transfer | 146 (102-173) | Â | Median age, months (IQR) at data transfer | 104 (62-143) |
Median months (IQR) on regimen | 17 (9-38) | Â | Median months (IQR) on regimen | 12 (4-18) |